Ethacizine

Ethacizine
Systematic (IUPAC) name

ethyl N-[10-[3-(diethylamino)propanoyl]phenothiazin-2-yl]carbamate
Clinical data
Trade names	Ethacizin
AHFS/Drugs.com	International Drug Names
Legal status	Prescription only (RU)
Pharmacokinetic data
Bioavailability	~40% (oral)^[1]
Protein binding	90%
Metabolism	Extensive hepatic
Biological half-life	2.5 hours
Identifiers
CAS Number	33414-33-4^Y
ATC code	C01BC09
PubChem	CID 107841
ChemSpider	96982^Y
UNII	FE5SPV1Z6G^Y
Chemical data
Formula	C₂₂H₂₇N₃O₃S
Molar mass	413.54 g/mol
SMILES CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)NC(=O)OCC
InChI InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27)^Y Key:PQXGNJKJMFUPPM-UHFFFAOYSA-N^Y

Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.^[1]

It is manufactured under the brand name Ethacizin (Этацизин) by Olainfarm.^[2]

References

1 2 "Этацизин (Ethacyzin) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 5 February 2014.
↑ "Этацизин—4DOKTOR.RU Drug Information Handbook" (in Russian). Retrieved 5 February 2014.

Antiarrhythmic agents (C01B)

Channel blockers

class I
(Na⁺ channel blockers)

class Ia (Phase 0→ and Phase 3→)	Ajmaline Disopyramide Lorajmine Prajmaline Procainamide^# Quinidine^# Sparteine

class Ib (Phase 3←)	IV (Lidocaine^#) enteral (Aprindine Mexiletine Tocainide)

class Ic (Phase 0→)	Encainide^‡ Ethacizine Flecainide Indecainide^‡ Lorcainide Moracizine^‡ Propafenone

class III
(Phase 3→, K⁺ channel blockers)

class IV
(Phase 4→, Ca²⁺ channel blockers)

Diltiazem
Verapamil^#

Receptor agonists
and antagonists

class II (Phase 4→, β blockers)	Nadolol Pindolol Propranolol cardioselective (Acebutolol Atenolol Esmolol Metoprolol)

A₁ agonist	Adenosine Benzodiazepines Barbiturates

M₂	muscarinic antagonist: Atropine Disopyramide Quinidine muscarinic agonist: Digoxin

α receptors	Amiodarone Bretylium Quinidine Verapamil

Ion transporters

Na⁺/ K⁺-ATPase	Digoxin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, June 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.